The Genomic, Transcriptomic, and Immunological Landscape of TROP2 in Solid Tumors
Asaad Trabolsi, Samuel Kareff, Estelamari Rodriguez, Harris Krause, Heng Tan, Dan Morgenstern-Kaplan, Emmanuel Antonarakis, Emil
Lou, Misako Nagasaka, Sandra Algaze, Heinz-Josef Lenz, Stephen Liu, Balazs Halmos, Dave Hoon, Andreas Seeber, Patrick Ma, Wafik El-
Deiry, Ari Vanderwalde, George Sledge, Gilberto Lopes
The genomic landscape of high versus low TACSTD2 expressors varied widely by cancer type.
Significant but small difference in TACSTD2 expression was observed between primary and metastatic sites.
There was an increased prevalence of T Cellinflamed tumors in the top quartile of TACSTD2 expressors across investigated tumor types.
High expression of TACSTD2 was associated with worse overall survival in Breast, CRC and PDAC tumors.
The association of TACSTD2 expression with KRAS, TP53 and ARID1A mutations and T cell inflamed tumors (ICI responsive) should be considered as possible combination therapies with TROP2 targeting antibody drug conjugates.